MetaCap

Parabilis Medicines Inc. (PBLS)

NASDAQ: PBLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

27.44-0.185 (-0.67%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PBLS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.62
52-week range
22.66 – 42.49
Day range
26.50 – 28.52
Volume / Avg
1.25M / 975.55K
Beta
—

52-week range

$22.66$42.49

PBLS stock today

Shares of Parabilis Medicines (PBLS) finished lower on Nov 20 at $27.44, a drop of 0.67% or $0.185 per share, versus the S&P 500's 3.70% decline. Shares are 35.4% below their 52-week high of $42.49, set on Sep 18, 2026 and 21.1% above the 52-week low of $22.66, in the middle of the past year's range. Parabilis Medicines has posted a net loss over the last twelve months (EPS of -$3.62), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Parabilis Medicines

Company profile

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Mathai Mammen M.D., Ph.D.
Headquarters
Cambridge, MA
Employees
145
IPO year
2026

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$41.00+49.42%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $39.00High $45.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.36 vs $-0.40
Surprise
+10.00%

PBLS news

All PBLS news

Parabilis Medicines peers

Health Care sector
PBLS peer companies
CompanyPrice% ChgMarket capCompare
IRONDisc Medicine Inc.75.14-1.27%$3.42Bvs PBLS
ELVNEnliven Therapeutics Inc.46.53+0.26%$3.42Bvs PBLS
VRDNViridian Therapeutics Inc.29.96-4.71%$3.40Bvs PBLS
AMLXAmylyx Pharmaceuticals Inc.26.02-0.69%$3.35Bvs PBLS
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs PBLS
XENEXenon Pharmaceuticals Inc.37.04-1.38%$3.64Bvs PBLS
OGNOrganon & Co.13.89-0.14%$3.65Bvs PBLS
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs PBLS

Indexes, lists and sector

Parabilis Medicines stock FAQ

What is Parabilis Medicines's stock price today?

PBLS last traded at $27.44 as of Nov 20, 4:00 PM EST, down 0.67% on the day. Prices are delayed at least 15 minutes.

Who is Parabilis Medicines's CEO?

Dr. Mathai Mammen M.D., Ph.D. is the chief executive officer of Parabilis Medicines Inc., which has about 145 employees.

What is the PBLS 52-week high?

The 52-week high for PBLS is $42.49 and the 52-week low is $22.66. The stock is currently 35.4% below its high.

Compare PBLS